PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsnon-hodgkin lymphoma
MeSH D008228 - non-hodgkin lymphoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D008223:Lymphoma
79 Companies
11 Drugs
$
Success rate
D008228: 
Non-hodgkin lymphoma
59 Companies
24 Drugs
$
Success rate
D008224:Follicular lymphoma
11 Companies
10 Drugs
$
Success rate
D016393:B-cell lymphoma
15 Companies
7 Drugs
$
Success rate
D016399:T-cell lymphoma
0 Companies
0 Drugs
Success rate
D016400:Large-cell lymphoma immunoblastic
2 Companies
1 Drug
$
Success rate
D020522:Mantle-cell lymphoma
40 Companies
10 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaBleomycin Bleomycin  1996-06-01   
Ifosfamide, Mesna Ifosfamide/mesna  2002-02-26   
Vincristine Vincasar  1987-07-17   
Vincristine Vincristine  1999-09-01   
Plerixafor Plerixafor  2023-07-24   
Cisplatin Cisplatin  2000-05-16   
IngenusCarmustine Carmustine  2022-06-21   
MylanCladribine Cladribine  2011-10-06   
Fludarabine Fludarabine  2011-12-21   
Ifosfamide Ifosfamide  2012-11-26   
Mercaptopurine Mercaptopurine  2005-07-01   
Carmustine Carmustine  2023-03-03   
Bendamustine Bendamustine  2023-04-28   
Cisplatin Cisplatin  2012-04-18   
Rising PharmaceuticalsFludarabine Fludarabine  2012-10-16   
Johnson & JohnsonCladribine Leustatin  1993-02-26   
GSKTositumomab, Sodium iodide i 131 Bexxar  2003-06-27   
RocheRituximab MabThera  1998-06-02   
CiplaBleomycin Bleomycin  2019-03-11   
SandozFludarabine Fludarabine  2007-09-21   
Rituximab Rixathon  2017-06-15   
Rituximab Riximyo  2017-06-15   
SanofiFludarabine Fludara  1991-04-18   
Plerixafor Mozobil 2023-07-22 2008-12-15   
Fludarabine Oforta 2022-12-20 2008-12-18   
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
72%
187/258
Phase 2
29%
76/259
Phase 3
40%
47/117
Approved: 25Overall Success rate: 9%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Vincristine sulfate,
Cisplatin,
Bleomycin,
Vincristine,
Calcium dobesilate,
Sodium lactate,
Microcrystalline cellulose
Mylan
Mercaptopurine
Johnson & Johnson
Calcium dobesilate,
ONAMETOSTAT,
Palifosfamide
GSK
Tositumomab,
Sodium iodide i 131,
Tositumomab 131i,
Antithrombin iii,
Sodium lactate,
Iboctadekin,
Microcrystalline cellulose,
Gsk461364
Roche
Rituximab,
Transplatin,
Antithrombin iii,
Iberdomide,
Tiragolumab,
Idasanutlin,
Calcium dobesilate,
Terfenadine,
Pixantrone,
Sodium chloride,
Emactuzumab,
Palifosfamide,
SELICRELUMAB,
Dcds0780a,
Rituxumab
Cipla
Bleomycin
Sandoz
Rituximab
Sanofi
Plerixafor,
Fludarabine,
Fludarabine phosphate,
Mycophenolate sodium,
Tbo-filgrastim,
Ziv-aflibercept,
Cilmostim,
Lenograstim,
Mitoguazone,
Regramostim,
Molgramostim,
Sodium chloride,
Sodium lactate,
Microcrystalline cellulose
Merck Sharp & Dohme
Vitamin e,
Cilmostim,
Dinaciclib,
Calcium dobesilate,
Tropisetron,
Regramostim,
Molgramostim,
Sodium chloride,
Sodium lactate,
Albinterferon alfa-2b,
Microcrystalline cellulose,
Retinol,
Mk-4280,
Flt3l
Takeda
Brentuximab vedotin,
TAK-981
Eli Lilly
Vincristine sulfate,
Vincristine,
Transplatin,
Enzastaurin,
MERESTINIB,
SAMOTOLISIB
1
2
3
4
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use